The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation

Oncology (Switzerland)

Volumn 90, Issue 5, 2016, Pages 239-247

  Charalampakis, Nikolaos ^a   Nogueras González, Graciela M ^a   Elimova, Elena ^a   Wadhwa, Roopma ^a   Shiozaki, Hironori ^a   Shimodaira, Yusuke ^a   Blum, Mariela A ^a   Rogers, Jane E ^a   Harada, Kazuto ^a   Matamoros, Aurelio ^a   Sagebiel, Tara ^a   Das, Prajnan ^a   Minsky, Bruce D ^a   Lee, Jeffrey H ^a   Weston, Brian ^a   Bhutani, Manoop S ^a   Estrella, Jeannelyn S ^a   Badgwell, Brian D ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoradiation response; Gastric adenocarcinoma; Histologic grade; Predictive factors; Signet ring cells

Indexed keywords

FLUOROPYRIMIDINE; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL COMPONENT; CELLS; CHEMORADIOTHERAPY; DISEASE ASSOCIATION; ENDOSCOPIC BIOPSY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE; RECURRENCE FREE SURVIVAL; SIGNET RING CELL; STOMACH ADENOCARCINOMA; TREATMENT RESPONSE; ADENOCARCINOMA; CANCER GRADING; CARCINOMA, SIGNET RING CELL; KAPLAN MEIER METHOD; NEOADJUVANT THERAPY; PATHOLOGY; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PROCEDURES; PROGNOSIS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SIGNET RING CELL; CHEMORADIOTHERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROGNOSIS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84964053158     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000443506     Document Type: Article

References (25)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:E359-E386.
2. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30.
3. Agboola O: Adjuvant treatment in gastric cancer. Cancer Treat Rev 1994; 20: 217-240.
4. Bonenkamp JJ, Hermans J, Sasako M, Welvaart K, Songun I, Meyer S, et al: Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340: 908-914.
5. de Manzoni G, Pedrazzani C, Pasini F, Durante E, Gabbani M, Grandinetti A, et al: Pattern of recurrence after surgery in adenocarcinoma of the gastro-oesophageal junction. Eur J Surg Oncol 2003; 29: 506-510.
6. Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K: Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 2000; 87: 353-357.
7. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008; 359: 453-462.
8. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
9. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
10. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al: Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012; 30: 2327-2333.
11. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, et al: Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004; 22: 2774-2780.
12. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, et al: Paclitaxelbased chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005; 23: 1237-1244.
13. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, et al: Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 2006; 24: 3953-3958.
14. Jiang Y, Ajani JA: Multidisciplinary management of gastric cancer. Curr Opin Gastroenterol 2010; 26: 640-646.
15. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851-856.
16. NCCN guidelines for Gastric Cancer, version 3. 2015. http://www.nccn.org/professionals/ physician-gls/pdf/gastric.pdf.
17. Piessen G, Messager M, Leteurtre E, Jean- Pierre T, Mariette C: Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg 2009; 250: 878-887.
18. Piessen G, Amielh D, Messager M, Vinatier E, Leteurtre E, Triboulet JP, et al: Is pretreatment endoscopic biopsy a good predictor of signet ring cell histology in gastric carcinoma? World J Surg 2012; 36: 346-354.
19. Siewert JR, Stein HJ: Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998; 85: 1457-1459.
20. Greene FL, Page DL, Fleming ID, et al: AJCC Cancer Staging Manual, ed 6. 2002.
21. Bosman FT, et al (eds): WHO Classification of Tumours of the Digestive System, ed 4. Lyon, IARC Press, 2010.
22. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, et al: Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005; 103: 1347-1355.
23. Wu TT, Chirieac LR, Abraham SC, Krasinskas AM, Wang H, Rashid A, et al: Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol 2007; 31: 58-64.
24. Edge SB, Byrd DR, Compton CC, et al: AJCC Cancer Staging Manual, ed 7. 2010.
25. Patel VR, Hofstetter WL, Correa AM, Agarwal A, Rashid A, Bhutani MS, et al: Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. Ann Thorac Surg 2014; 98: 1064-1071.